BioCentury | Apr 27, 2020
Product Development

After hitting primary endpoint, Axsome planning second trial in Alzheimer’s agitation

...disorder (see “Phase III Success” ). Also due in 4Q20 is an NDA submission for AXS-07...
BioCentury | Apr 7, 2020
Product Development

April 6 Quick Takes: Second anemia approval for BMS, Acceleron therapy; plus EU approves trio of metabolic disease drugs, Dicerna-Alnylam and Axsome

...product." Axsome adds second migraine indication to Phase III successes Axsome Therapeutics Inc. (NASDAQ:AXSM) said AXS-07...
...for AXS-07 to treat acute migraine. Monday's readout comes three months after the company showed AXS-07...
..."Migraine Readout Completes December Hat Trick for Surging Axsome" ). Targets GLP-1 - Glucagon-like peptide-1 BioCentury Staff AXS-07 bempedoic...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...success stories of the fourth quarter, reporting a trio of positive, late-stage readouts in December. AXS-07...
BioCentury | Dec 30, 2019
Clinical News

Migraine readout completes December hat trick for surging Axsome

...planned 2H20 NDA submission that could allow the company to carve out a niche for AXS-07...
...showing superiority to each of its components in the study’s active comparator arms. MOMENTUM studied AXS-07...
...a year ago; they traded below $14 intraday as recently as Oct. 1. In MOMENTUM, AXS-07...
BioCentury | Apr 6, 2019
Finance

Everybody up

...the Phase III MOMENTUM trial of AXS-07 to treat migraine under a Special Protocol Assessment. AXS-07...
BioCentury | Dec 8, 2017
Financial News

Axsome raises $9.5M in direct offering

...warrants are exercisable at $5.25. Axsome will use the proceeds to fund clinical development of AXS-07...
...II/III testing to treat agitation in Alzheimer's disease. Axsome Therapeutics Inc. (NASDAQ:AXSM), New York, N.Y. Allison Johnson AXS-02 AXS-05 AXS-07 Axsome...
Items per page:
1 - 6 of 6